Mercado de diagnóstico de cáncer de hígado: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00003017
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 181
Buy Now

Se prevé que el mercado de diagnóstico del cáncer de hígado alcance los 15.951,77 millones de dólares en 2028, frente a los 9.323,14 millones de dólares en 2021. Se estima que el mercado crecerá a una tasa compuesta anual del 8,0 % entre 2021 y 2028.

El cáncer de hígado comienza en las células del hígado. Se pueden formar múltiples tipos de cáncer en el hígado. El carcinoma hepatocelular se considera el cáncer de hígado más común y comienza en el hepatocito. Según la Sociedad Estadounidense de Oncología Clínica (ASCO), alrededor del 80% de los cánceres primarios de hígado en adultos son carcinomas hepatocelulares. Otros tipos de cáncer de hígado incluyen el hepatoblastoma y el colangiocarcinoma intrahepático. Estos se consideran menos comunes. El diagnóstico del cáncer de hígado comprende técnicas utilizadas para la identificación y confirmación del cáncer de hígado.

Perspectivas estratégicas

El crecimiento del mercado de diagnóstico del cáncer de hígado se atribuye a la creciente prevalencia del cáncer de hígado y al aumento de las inversiones en I+D en el desarrollo de nuevas pruebas de diagnóstico. Por otro lado, el alto costo de las soluciones de diagnóstico de cáncer de hígado tecnológicamente avanzadas obstaculiza el crecimiento del mercado.

regiones lucrativas en el mercado de diagnóstico de cáncer de hígado


perspectivas del mercado< br />Crecientes inversiones en I+D para el desarrollo de nuevas pruebas de diagnóstico

La capacidad de diagnosticar con precisión la progresión del cáncer de hígado es fundamental para seleccionar la opción de tratamiento adecuada. Además, varias empresas y organizaciones han tomado enormes iniciativas para desarrollar e implementar soluciones innovadoras para la identificación temprana de esta enfermedad en respuesta a la creciente demanda. Por ejemplo, en marzo de 2020, la puntuación Elecsys GALAD de Roche Holding AG recibió el estatus de dispositivo innovador de la Administración de Alimentos y Medicamentos de EE. UU. para la detección temprana de una forma avanzada de cáncer de hígado. La calculadora del fabricante de medicamentos suizo combina factores que incluyen la edad, el sexo y los resultados de biomarcadores para detectar el carcinoma hepatocelular en etapa temprana, que es la forma más común de cáncer de hígado. Además, la puntuación Elecsys GALAD está diseñada para ayudar a los médicos proporcionándoles un diagnóstico oportuno y preciso del carcinoma hepatocelular. El gasto en investigación y desarrollo (I+D) en 2021 fue de 14,65 mil millones de dólares y en 2020 fue de 13,17 mil millones de dólares. El gasto en I+D creció un 14 % de forma básica en F. Hoffmann-La Roche Ltd, impulsado principalmente por inversiones de última fase en oncología, oftalmología y atención sanitaria personalizada. En 2021, la inversión en I+D en la división de diagnóstico fue de US$ 1.878,92 millones. De manera similar, en noviembre de 2019, EXACT Sciences Corporation recibió la designación innovadora de la Administración de Alimentos y Medicamentos (FDA) para su prueba de sangre para la detección temprana del cáncer de hígado. Además, en junio de 2020, científicos de los Institutos Nacionales de Salud (NIH) desarrollaron análisis de sangre para ayudar a mejorar la detección del cáncer de hígado, dirigidos por investigadores del Instituto Nacional del Cáncer (NCI). Además, en junio de 2019, investigadores de la Universidad Johns Hopkins diseñaron CancerSEEK, una prueba de biopsia líquida. La prueba fue diseñada para diagnosticar múltiples cánceres, incluidos los de estómago, hígado, ovario y esófago, en una etapa temprana, lo que facilita el tratamiento temprano. Por lo tanto, las crecientes inversiones en I+D y el desarrollo de pruebas de diagnóstico para la detección del cáncer de hígado están impulsando el mercado del diagnóstico del cáncer de hígado.

Información basada en tipos

El diagnóstico global del cáncer de hígado El mercado, según el tipo, se segmenta en pruebas de laboratorio, endoscopia, imágenes, biopsia y otros. El mercado para el segmento de pruebas de laboratorio se segmenta aún más en análisis de sangre y biomarcadores. El segmento de pruebas de laboratorio tuvo la mayor participación del mercado en 2021. Sin embargo, se prevé que el segmento de imágenes registre una tasa compuesta anual del 8,5% en el mercado durante el período de pronóstico.  

Mercado de diagnóstico de cáncer de hígado, por tipo: 2021 y 2028


Información basada en el usuario final

Según el usuario final, el mercado mundial de diagnóstico del cáncer de hígado se segmenta en hospitales y laboratorios de diagnóstico, institutos académicos y de investigación, y laboratorios CRO. El segmento de hospitales y laboratorios de diagnóstico tuvo la mayor participación de mercado en 2021, ya que los hospitales brindan instalaciones de atención médica a través de equipos científicos especializados. Se asigna un equipo de personal capacitado para abordar, investigar y solucionar los problemas asociados con la ciencia médica moderna en el hospital. Varios equipos de investigación médica trabajan constantemente en la introducción de tecnologías innovadoras relacionadas con los métodos de diagnóstico y otras actividades en el campo médico. Los pacientes generalmente prefieren el hospital para recibir tratamiento contra el cáncer de hígado debido a la disponibilidad de opciones de tratamiento avanzadas. Los hospitales son el punto de atención a los pacientes. Además, se prevé que el mismo segmento registre una tasa compuesta anual del 8,5 % en el mercado durante el período de pronóstico.

Los lanzamientos y aprobaciones de productos son estrategias comúnmente adoptadas por las empresas para expandir su huella global y sus carteras de productos para dominar el mercado. Cuota de mercado de diagnóstico de cáncer de hígado. Además, los actores del mercado se centran en la estrategia de asociación para ampliar su clientela, lo que, a su vez, les permite mantener su marca a nivel mundial. Se prevé que la cuota de mercado de diagnóstico del cáncer de hígado prospere con el desarrollo de nuevos productos innovadores por parte de los actores del mercado.

Perfiles de la empresa

  • Abbott
  • BioMerieux SA
  • F. HOFFMANN-LA ROCHE LTD
  • Illumina, Inc.
  • Koninklijke Philips NV
  • QIAGEN
  • Siemens Healthineers AG
  • THERMO FISHER SCIENTIFIC INC.
  • GE Healthcare
  • Perspectum
  • Helio, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are liver cancer diagnostics?

The abnormal proliferation of cells in the body is referred to as cancer. Cancer of the liver starts in the cells of the liver. The liver can develop a variety of cancers. Hepatocellular carcinoma is the most prevalent type of liver cancer, and it starts in the hepatocyte. Some liver cancers can be detected through screening in persons who are at high risk but do not have symptoms, but most liver cancers are discovered when they produce symptoms. To detect liver disease, a series of blood tests known as liver function tests and imaging studies are employed.

What are the driving factors for the liver cancer diagnostics market across the globe?

Key factors that are driving the growth of this market are the rising prevalence of liver cancer and rising R&D investments for the development of novel diagnostic testing are expected to boost the market growth for liver cancer diagnostics over the years.

What is the market CAGR value of the liver cancer diagnostics market during the forecast period?

The CAGR value of the liver cancer diagnostics market during the forecasted period of 2021-2028 is 8.0%.

Which type led the liver cancer diagnostics market?

The laboratory tests segment held the largest share of the market in the global liver cancer diagnostics market and held the largest market share of 39.61% in 2021.

Which end user held the largest share in the liver cancer diagnostics market?

The hospitals and diagnostic laboratories segment dominated the global liver cancer diagnostics market and accounted for the largest market share of 48.56% in 2021.

Who are the key players in the Liver Cancer Diagnostics market?

The liver cancer diagnostics market majorly consists of players such as Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; Helio, Inc amongst others.

Which are the top companies that hold the market share in liver cancer diagnostics market?

Koninklijke Philips N.V. and Siemens Healthineers AG are the top two companies that hold huge market shares in the liver cancer diagnostics market.

Which region is expected to witness significant demand for the liver cancer diagnostics market in the coming years?

The North America region secures a substantial share of the global liver cancer diagnostics market. The growth of the market in the region is attributed by the rising prevalence of liver cancer. In North America, the US is the largest market for liver cancer diagnostics. The growth of this market is primarily driven by the growing prevalence of liver cancer diseases, technological advancements and developments in the US are going to accelerate the growth of this market in this country.

What is the COVID 19 impact on the Liver Cancer Diagnostics market in the coming years?

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented problems to healthcare systems, and patients with liver cancer (LC) may have been particularly affected. COVID-19 may aggravate pre-existing chronic liver damage in HCC patients, complicating cancer treatment. Cancer patients, especially those who have just completed treatment, are at a higher risk of infection and have a poorer prognosis. The first wave of the COVID-19 epidemic had a huge influence on liver cancer patients' normal care. Patients' outcomes may have been considerably harmed as a result of changes to screening, diagnostic, and treatment algorithms. The benefits and drawbacks of the tactics used will be reported through ongoing data collecting and future analysis, assisting future decision-making. However, in the long run, as the vaccination schedule is established and the transmission rate decreases, healthcare systems will return to normal and is expected to experience increased demand for liver cancer diagnostics.

The List of Companies - Liver Cancer Diagnostic Market

  1. Abbott
  2. BioMerieux SA
  3. F. HOFFMANN-LA ROCHE LTD
  4. Illumina, Inc.
  5. Koninklijke Philips N.V
  6. QIAGEN
  7. Siemens Healthineers AG
  8. THERMO FISHER SCIENTIFIC INC.
  9. GE Healthcare
  10. Perspectum
  11. Helio, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports